Skip to main content

Table 2 Clinical characteristics of the two study participants who tested negative for autoantibodies (GADA, IA-2A, and ICA) at 1 month and who converted to positivity for GADA (patient 2) at 12 months or IA-2A (patient 24 (carrier of the Arg1530Cys mutation of the ABCC8)) at 6 and 12 months after the diagnosis of type 1 diabetes

From: Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies

Patient

Age

(years)

Sex

BMI

(kg/m2)

HbA1C0

(%)

IDAA1C 1

IDAA1C 6

IDAA1C 12

Ins dose1

(U/kg/day)

ins dose6

(U/kg/day)

Ins dose12

(U/kg/day)

Cpep1

(pmol/L)

Cpep6

(pmol/L)

Cpep12

(pmol/L)

BGstim1

(mmol/L)

BGstim6

(mmol/L)

BGstim12

(mmol/L)

2

16.3

female

17

10.9

Na

11.1

11.7

0.54

0.73

0.59

120

10

10

14.2

20.7

13.2

24

14

male

16.4

12.4

11.3

10.6

12.8

0.63

0.73

0.98

356

308

218

13.9

21

20.6

  1. Abbreviations: Na, not available; BMI, body mass index; HBA1C0; HBA1C at diagnosis; IDAA1C 1, Insulin Dose Adjusted HbA1c (IDAA1C) at 1 month; IDAA1C 6, IDAA1C at 6 months; IDAA1C 12, IDAA1C at 12 months;; Ins dose1, insulin dose at 1 month; Ins dose6, insulin dose at 6 months; Ins dose12, insulin dose at 12 months; Cpep1, stimulated C-peptide at 1 month, Cpep6, stimulated C-peptide at 6 months; Cpep12, stimulated C-peptide at 12 months; BGstim1, 90 min glucose at 1 month; BGstim6, 90 min glucose at 6 months; BGstim12, 90 min glucose at 12 months;